The potential use of AKAP18δ as a drug target in heart failure patients

Q: What is the clinical evidence from this study?

Study design: Review. Population: Heart failure. Intervention: Targeting AKAP18delta.

Birgitte Lygren; Kjetil Taskén

doi:10.1517/14712598.8.8.1099

July 9, 2008Expert Opinion on Biological Therapy

The potential use of AKAP18δ as a drug target in heart failure patients

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does targeting AKAP18delta improve calcium reabsorption and protect the heart from adrenergic pacing in heart failure patients?

Structured PICO

Does targeting AKAP18delta improve calcium reabsorption and protect the heart from adrenergic pacing in heart failure patients?

P

Population

Heart failure patients (theoretical target population)

I

Intervention

Targeting AKAP18delta

Implication

Targeting AKAP18delta represents a potential novel therapeutic strategy for modulating calcium reabsorption and protecting the heart from adrenergic pacing in heart failure.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lygren et al. (2008) conducted a review in Heart failure. Targeting AKAP18delta was evaluated.

synapsesocial.com/papers/6a1ff99791899344c12e6d26 https://doi.org/10.1517/14712598.8.8.1099

Topics

Heart failure

HFrEF treatment

View Full Paper

Ask AI

Bookmark

Share

The potential use of AKAP18δ as a drug target in heart failure patients

Structured PICO

Implication

Discussion

Cite This Study

Topics

The potential use of AKAP18δ as a drug target in heart failure patients

Structured PICO

Implication

Discussion

Cite This Study

Keep reading

Topics

Keep reading